New hope for lung cancer patients who can't use standard immunotherapy alone
NCT ID NCT06711900
First seen Nov 17, 2025 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tests whether adding an experimental drug (SKB264) to standard immunotherapy (pembrolizumab) works better than chemotherapy plus immunotherapy for people with advanced non-squamous lung cancer that lacks a key protein (PD-L1 negative). About 432 adults whose cancer has spread or can't be removed by surgery will receive either the new combo or standard chemo-immunotherapy. The goal is to see if the new combo delays cancer growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Oriental Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.